The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges
Abstract
BACKGROUND: Multi-drug resistance (MDR) of cancer cells is an obstacle to effective chemotherapy of cancer. The ATP-binding cassette (ABC) transporters, including P-glycoprotein (ABCB1), MRP1 (ABCC1) and ABCG2, play an important role in the development of this resistance. An attractive approach to overcoming MDR is the inhibition of the pumping action of these transporters. Several inhibitors/modulators of ABC transporters have been developed, but cytotoxic effects and adverse pharmacokinetics have prohibited their use. The ongoing search for such inhibitors/modulators that can be applied in the clinic has led to three generations of compounds. The most recent inhibitors are more potent and less toxic than first-generation compounds, yet some are still prone to adverse effects, poor solubility and unfavorable changes in the pharmacokinetics of the anticancer drugs. OBJECTIVE: This review provides an update of the published work on the development of potent modulators to overcome MDR in cancer cells, their present status in clinical studies and suggestions for further improvement to obtain better inhibitors. METHODS: This review summarizes recent advances in the development of less toxic modulators, including small molecules and natural products. In addition, a brief overview of other novel approaches that can be used to inhibit ABC drug transporters mediating MDR has also been provided. CONCLUSION: The multifactorial nature of MDR indicates that it may be important to develop modulators that can simultaneously inhibit both the function of the drug transporters and key signaling pathways, which are responsible for development of this phenomenon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 6×
“The active efflux of these chemotherapeutic drugs by ABCG2 can ultimately result in the development of MDR if overexpressed in cancer cells [4] .”
BackgroundInfluentialHannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 2×
“Soon after the discovery of MRP1 in 1992 [11] , the hunt for modulators of this ABC transporter became the research topic of interest.”
BackgroundAnticancer potential of curcumin: preclinical and clinical studies.
Aggarwal, B. B., Kumar, A. J., & Bharti, A. C. (2003) · PubMed · Cited by 3,017
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
P-glycoprotein: from genomics to mechanism
Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206948 · Cited by 1,074
Self-citationInagaki, N., Gonoi, T., Iv, J. P. C., Wang, C.-Z., Aguilar-Bryan, L., Bryan, J., & Seino, S. (1996) · Neuron · doi:10.1016/s0896-6273(00)80124-5 · Cited by 974
von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
P-Glycoprotein, a gatekeeper in the blood–brain barrier
Schinkel, A. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00085-4 · Cited by 960
Miyake, K., Mickley, L. A., Litman, T., Zhan, Z., Robey, R. W., Cristensen, B., Brangi, M., Greenberger, L., Dean, M. C., Fojo, T., et al. (1999) · PubMed · Cited by 929
Allikmets, R., Schriml, L. M., Hutchinson, A. A., Romano-Spica, V., & Dean, M. C. (1998) · PubMed · Cited by 918
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Allen, J. D., van Loevezijn, A., Rademaker-Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G., & Schinkel, A. H. (2002) · PubMed · Cited by 814
Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726
The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme
Krishnamurthy, P., Ross, D. D., Nakanishi, T., Bailey-Dell, K., Zhou, S., Mercer, K. E., Sarkadi, B., Sorrentino, B. P., & Schuetz, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313599200 · Cited by 661
Li, L., Braiteh, F. S., & Kurzrock, R. (2005) · Cancer · doi:10.1002/cncr.21300 · Cited by 644
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 638
Loe, D. W., Almquist, K. C., Deeley, R. G., & Cole, S. P. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9675 · Cited by 560
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Rabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W., & Greenberger, L. M. (2000) · PubMed · Cited by 487
Kruijtzer, C. M. F., Beijnen, J. H., Rosing, H., ten Bokkel Huinink, W. W., Schot, M., Jewell, R. C., Paul, E. M., & Schellens, J. H. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.116 · Cited by 464
Reid, G., Wielinga, P., Zelcer, N., van der Heijden, I., Kuil, A., de Haas, M., Wijnholds, J., & Borst, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1033060100 · Cited by 463
ABC Transporters as Phenotypic Markers and Functional Regulators of Stem Cells
Bunting, K. D. (2002) · STEM CELLS · doi:10.1002/stem.200011 · Cited by 458
Therapeutic Applications of Oligonucleotides
Crooke, S. T. (1992) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.32.040192.001553 · Cited by 446
Wijnholds, J., Evers, R., van Leusden, M. R., Mol, C. A. A. M., Zaman, G. J. R., Mayer, U., Beijnen, J. H., Valk, M. V. D., Krimpenfort, P., & Borst, P. (1997) · Nature Medicine · doi:10.1038/nm1197-1275 · Cited by 432
Jonker, J. W., Merino, G., Musters, S., van Herwaarden, A. E., Bolscher, E., Wagenaar, E., Mesman, E., Dale, T. C., & Schinkel, A. H. (2005) · Nature Medicine · doi:10.1038/nm1186 · Cited by 423
Localisation of breast cancer resistance protein in microvessel endothelium of human brain
Cooray, H. C., Blackmore, C. G., Maskell, L., & Barrand, M. A. (2002) · NeuroReport · doi:10.1097/00001756-200211150-00014 · Cited by 419
Structural, mechanistic and clinical aspects of MRP1
Hipfner, D. R., Deeley, R. G., & Cole, S. P. C. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00168-6 · Cited by 412
Inagaki, N., Tsuura, Y., Namba, N., Masuda, K., Gonoi, T., Horie, M., Seino, Y., Mizuta, M., & Seino, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.5691 · Cited by 405
Role of the breast cancer resistance protein (ABCG2) in drug transport
Mao, Q. (2005) · The AAPS Journal · doi:10.1208/aapsj070112 · Cited by 405
Gekeler, V., Ise, W., Sanders, K. H., Ulrich, W. R., & Beck, J. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1344 · Cited by 396
Loe, D. W., Deeley, R. G., & Cole, S. P. C. (1998) · PubMed · Cited by 394
Pharmacological Strategies for Overcoming Multidrug Resistance
Nobili, S., Landini, I., Giglioni, B., & Mini, E. (2006) · Current Drug Targets · doi:10.2174/138945006777709593 · Cited by 393
Biology of the multidrug resistance-associated protein, MRP
Loe, D. W., Deeley, R. G., & Cole, S. P. C. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00046-9 · Cited by 367
Boesch, D., Gavériaux‐Ruff, C., Jachez, B., Pourtier, A., Bollinger, P., & Loor, F. (1991) · PubMed · Cited by 360
Wijnholds, J., de Lange, E. C. M., Scheffer, G. L., van den Berg, D.-J., Mol, C. A. A. M., van der Valk, M., Schinkel, A. H., Scheper, R. J., Breimer, D. D., & Borst, P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8267 · Cited by 360
Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport
Zhang, S., Yang, X., & Morris, M. E. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.5.1208 · Cited by 359
ROLE OF ABCG2/BCRP IN BIOLOGY AND MEDICINE
Krishnamurthy, P., & Schuetz, J. D. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141238 · Cited by 356
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Cascorbi, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.009 · Cited by 355
(2001) · PubMed · Cited by 350
Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition
Robey, R. W., Steadman, K., Polgar, O., Morisaki, K., Blayney, M., Mistry, P., & Bates, S. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3298 · Cited by 350
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Fox, E., & Bates, S. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.447 · Cited by 350
High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter
Özvegy-Laczka, C., Hegedűs, T., Várady, G., Ujhelly, O., Schuetz, J. D., Váradi, A., Kéri, G., Őrfi, L., Német, K., & Sarkadi, B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1485 · Cited by 340
Li, L., Ahmed, B., Mehta, K., & Kurzrock, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0556 · Cited by 332
Houghton, P. J., Germain, G. S., Harwood, F. C., Schuetz, J. D., Stewart, C. F., Buchdunger, E., & Traxler, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3344 · Cited by 323
Interactions of the Human Multidrug Resistance Proteins MRP1 and MRP2 with Organic Anions
Bakos, É., Evers, R., Sinkó, E., Váradi, A., Borst, P., & Sarkadi, B. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26477-4 · Cited by 322
Zhang, S., & Morris, M. E. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044412 · Cited by 309
Berruti, A., Terzolo, M., Sperone, P., Pia, A., Della Casa, S., Gross, D. J., Carnaghi, C., Casali, P., Porpiglia, F., Mantero, F., et al. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01025 · Cited by 308
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302
Wu, H., Hait, W. N., & Yang, J. (2003) · PubMed · Cited by 289
Collnot, E.-M., Baldes, C., Wempe, M. F., Kappl, R., Hüttermann, J., Hyatt, J. A., Edgar, K. J., Schaefer, U. F., & Lehr, C.-M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060121r · Cited by 280
Imai, Y., Tsukahara, S., Asada, S., & Sugimoto, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0078 · Cited by 280
Pavek, P., Merino, G., Wagenaar, E., Bolscher, E., Novotna, M., Jonker, J. W., & Schinkel, A. H. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073916 · Cited by 278
van Herwaarden, A. E., Jonker, J. W., Wagenaar, E., Brinkhuis, R. F., Schellens, J. H. M., Beijnen, J. H., & Schinkel, A. H. (2003) · PubMed · Cited by 269
Evers, R., Zaman, G. J., van Deemter, L., Jansen, H., Calafat, J., Oomen, L. C., Oude Elferink, R. P., Borst, P., & Schinkel, A. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118535 · Cited by 260
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., & Callaghan, R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702807 · Cited by 258
Renes, J., De Vries, E. G. E., Nienhuis, E. F., Jansen, P. L. M., & Müller, M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702360 · Cited by 256
Lee, K.-D., Hong, K., & Papahadjopoulos, D. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90086-2 · Cited by 240
An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Takara, K., Sakaeda, T., & Okumura, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206775201965 · Cited by 236
Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles
Breedveld, P., Zelcer, N., Pluim, D., Sönmezer, O., Tibben, M. M., Beijnen, J. H., Schinkel, A. H., van Tellingen, O., Borst, P., & Schellens, J. H. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4062 · Cited by 233
El-Sheikh, A. A. K., van den Heuvel, J. J. M. W., Koenderink, J. B., & Russel, F. G. M. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110379 · Cited by 232
Maliepaard, M., van Gastelen, M. A., Tohgo, A., Hausheer, F. H., van Waardenburg, R. C. A. M., de Jong, L. A., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2001) · PubMed · Cited by 231
Chearwae, W., Anuchapreeda, S., Nandigama, K., Ambudkar, S. V., & Limtrakul, P. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.009 · Cited by 229
Self-citationRandolph, G. J., Beaulieu, S., Pope, M., Sugawara, I., Hoffman, L., Steinman, R. M., & Muller, W. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6924 · Cited by 227
van Herwaarden, A. E., Wagenaar, E., Merino, G., Jonker, J. W., Rosing, H., Beijnen, J. H., & Schinkel, A. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01621-06 · Cited by 226
Interaction of the breast cancer resistance protein with plant polyphenols
Cooray, H. C., Janvilisri, T., van Veen, H. W., Hladky, S. B., & Barrand, M. A. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.03.040 · Cited by 226
Drach, J., Gsur, A., Hamilton, G., Zhao, S., Angerler, J., Fiegl, M., Zojer, N., Raderer, M., Haberl, I., Andreeff, M., et al. (1996) · Blood · doi:10.1182/blood.v88.5.1747.1747 · Cited by 224
Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani
Wu, J. Y.-C., Fong, W.-F., Zhang, J.-X., Leung, C.-H., Kwong, H.-L., Yang, M.-S., Li, D., & Cheung, H.-Y. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01946-0 · Cited by 221
Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport
Sims-Mourtada, J., Izzo, J. G., Ajani, J., & Chao, K. S. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210356 · Cited by 217
Gupta, A., Zhang, Y., Unadkat, J. D., & Mao, Q. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065342 · Cited by 216
van Vlerken, L. E., Duan, Z., Seiden, M. V., & Amiji, M. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1648 · Cited by 214
Limtrakul, P., Chearwae, W., Shukla, S., Phisalphong, C., & Ambudkar, S. V. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9302-8 · Cited by 208
Self-citationHegedűs, T., Őrfi, L., Seprődi, A., Váradi, A., Sarkadi, B., & Kéri, G. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00095-9 · Cited by 207
Wijnholds, J., Scheffer, G. L., van der Valk, M., van der Valk, P., Beijnen, J. H., Scheper, R. J., & Borst, P. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.797 · Cited by 202
Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
Nieth, C., Priebsch, A., Stege, A., & Lage, H. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00523-4 · Cited by 200
Allen, J. D., Brinkhuis, R. F., van Deemter, L., Wijnholds, J., & Schinkel, A. H. (2000) · PubMed · Cited by 200
Brendel, C., Scharenberg, C., Dohse, M., Robey, R. W., Bates, S. E., Shukla, S., Ambudkar, S. V., Wang, Y., Wennemuth, G., Burchert, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404638 · Cited by 200
Self-citationAhmed-Belkacem, A., Pozza, A., Muñoz-Martínez, F., Bates, S. E., Castanys, S., Gamarro, F., Di Pietro, A., & Pérez-Victoria, J. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1817 · Cited by 196
Kuppens, I. E. L. M., Witteveen, E. O., Jewell, R. C., Radema, S. A., Paul, E. M., Mangum, S. G., Beijnen, J. H., Voest, E. E., & Schellens, J. H. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2414 · Cited by 177
Ludwig, J. A., Szakács, G., Martin, S. E., Chu, B. F., Cardarelli, C., Sauna, Z. E., Caplen, N. J., Fales, H. M., Ambudkar, S. V., Weinstein, J. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3322 · Cited by 176
Self-citationLiposome-based approaches to overcome anticancer drug resistance
Mamot, C., Drummond, D. C., Hong, K., Kirpotin, D. B., & Park, J. W. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00082-7 · Cited by 170
Minderman, H., O’Loughlin, K. L., Pendyala, L., & Baer, M. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0914-3 · Cited by 170
Role Reversal for Anticancer Agents
Pardee, A. B. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.4.22 · Cited by 165
Wu, C., Calcagno, A. M., Hladky, S. B., Ambudkar, S. V., & Barrand, M. A. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04888.x · Cited by 159
Self-citationHirrlinger, J., König, J., Keppler, D., Lindenau, J., Schulz, J. B., & Dringen, R. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00101.x · Cited by 158
Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3
Kim, S., Kwon, H., Chi, D.-W., Shim, J.-H., Park, J.-D., Lee, Y. H., Pyo, S., & Rhee, D. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01446-6 · Cited by 156
Dantzig, A., Law, K., Cao, J., et al. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373903 · Cited by 156
Friedenberg, W. R., Rué, M., Blood, E., Dalton, W. S., Shustik, C., Larson, R. A., Sonneveld, P., & Greipp, P. R. (2006) · Cancer · doi:10.1002/cncr.21666 · Cited by 153
Sandler, A. B., Gordon, M. S., de Alwis, D. P., Pouliquen, I. J., Green, L., Marder, P., Chaudhary, A. K., Fife, K., Battiato, L. A., Sweeney, C. J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0644 · Cited by 151
Nakanishi, T., Shiozawa, K., Hassel, B. A., & Ross, D. D. (2006) · Blood · doi:10.1182/blood-2005-10-4020 · Cited by 148
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P. R., Villalona, M. A., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L. A., Kraynak, M. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2964 · Cited by 146
Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance
Fu, L., Liang, Y.-J., Deng, L., Ding, Y. P., Chen, L., Ye, Y.-L., Yang, X., & Pan, Q. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0742-5 · Cited by 145
A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells.
FitzGerald, D. J., Willingham, M. C., CARDARELLI, C. O., Hamada, H., TSURUO, T., Gottesman, M. M., & PASTAN, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.12.4288 · Cited by 143
A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity
Henrich, C. J., Bokesch, H. R., Dean, M. C., Bates, S. E., Robey, R. W., Goncharova, E. I., Wilson, J. A., & McMahon, J. B. (2006) · SLAS DISCOVERY · doi:10.1177/1087057105284576 · Cited by 142
Agrawal, M., Abraham, J., Balis, F. M., Edgerly, M., Stein, W. D., Bates, S. E., Fojo, T., & Chen, C. C. (2003) · PubMed · Cited by 135
BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers
Zhang, Y., Gupta, A., Wang, H., Zhou, L., Vethanayagam, R. R., Unadkat, J. D., & Mao, Q. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8384-4 · Cited by 130
Chearwae, W., Shukla, S., Limtrakul, P., & Ambudkar, S. V. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0087 · Cited by 130
Self-citationGupta, A., Dai, Y., Vethanayagam, R. R., Hébert, M. F., Thummel, K. E., Unadkat, J. D., Ross, D. D., & Mao, Q. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0173-6 · Cited by 126
TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2)
Merino, G., Jonker, J. W., Wagenaar, E., Pulido, M. M., Molina, A. J., Álvarez, A. I., & Schinkel, A. H. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003319 · Cited by 126
Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells
Kitagawa, S., Nabekura, T., & Kamiyama, S. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357044003 · Cited by 126
Sensitization of Cells Overexpressing Multidrug-Resistant Proteins by Pluronic P85
Batrakova, E. V., Li, S., Alakhov, V. Y., Elmquist, W. F., Miller, D. W., & Kabanov, A. V. (2003) · Pharmaceutical Research · doi:10.1023/a:1026179132599 · Cited by 125
Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3)
Lespine, A., Dupuy, J., Orlowski, S., Nagy, T., Glavinas, H., Krajcsi, P., & Alvinerie, M. (2005) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2005.11.002 · Cited by 123
Brooks, T. A., Minderman, H., O’Loughlin, K. L., Pera, P. J., Ojima, I., Baer, M. R., Bernacki, R. J., & Brooks, T. A. (2003) · PubMed · Cited by 119
Choi, C.-H., Kang, G. J., & Min, Y. (2003) · Planta Medica · doi:10.1055/s-2003-38483 · Cited by 116
Abdul‐Ghani, R., Serra, V., Győrffy, B., Jürchott, K., Solf, A., Dietel, M., & Schäfer, R. (2005) · Oncogene · doi:10.1038/sj.onc.1209201 · Cited by 115
Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H., Mitsuhashi, J., & Sugimoto, Y. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0426-7 · Cited by 114
Devalapally, H., Duan, Z., Seiden, M. V., & Amiji, M. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22886 · Cited by 110
Sugimoto, Y., Tsukahara, S., Imai, Y., Sugimoto, Y., Ueda, K., & Tsuruo, T. (2003) · PubMed · Cited by 110
A Role for P-Glycoprotein in Regulating Cell Death
Johnstone, R. W., Ruefli, A. A., Tainton, K. M., & Smyth, M. J. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009060314 · Cited by 109
Reversal of breast cancer resistance protein–mediated drug resistance by tryprostatin A
Woehlecke, H., Osada, H., Herrmann, A., & Lage, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11444 · Cited by 108
Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells
Yu, S.-T., Chen, T.-M., Tseng, S.-Y., & Chen, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.107 · Cited by 107
Shukla, S., Robey, R. W., Bates, S. E., & Ambudkar, S. V. (2006) · Biochemistry · doi:10.1021/bi060552f · Cited by 107
Self-citationChearwae, W., Wu, C., Chu, H., Lee, T. R., Ambudkar, S. V., & Limtrakul, P. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0052-1 · Cited by 107
Self-citationPeck, R. A., Hewett, J., Harding, M. W., Wang, Y., Chaturvedi, P. R., Bhatnagar, A., Ziessman, H. A., Atkins, F., & Hawkins, M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3130 · Cited by 106
van Zuylen, L., Sparreboom, A., van der Gaast, A., van der Burg, M. E., van Beurden, V., Bol, C. J., Woestenborghs, R., Palmer, P. A., & Verweij, J. (2000) · PubMed · Cited by 101
Nonprenylated Rotenoids, a New Class of Potent Breast Cancer Resistance Protein Inhibitors
Ahmed‐Belkacem, A., Macalou, S., Borrelli, F., Capasso, R., Fattorusso, E., Taglialatela‐Scafati, O., & Pietro, A. D. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061450q · Cited by 100
Mizuno, N., Suzuki, M., Kusuhara, H., Suzuki, H., Takeuchi, K., Niwa, T., Jonker, J. W., & Sugiyama, Y. (2004) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)02969-6 · Cited by 99
Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)
Gupta, A., Unadkat, J. D., & Mao, Q. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20963 · Cited by 97
Kemper, E. M., Cleypool, C. G. J., Boogerd, W. J., Beijnen, J. H., & van Tellingen, O. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0720-y · Cited by 97
Gerrard, G., Payne, E. M., Baker, R. J., Jones, D. T., Potter, M. N., Prentice, H. G., Ethell, M. E., McCullough, H., Burgess, M. A., Mehta, A. B., et al. (2004) · PubMed · Cited by 95
Tsuruo, T., Hamada, H., Sato, S., & Heike, Y. (1989) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1989.tb01688.x · Cited by 93
Acridone derivatives: Design, synthesis, and inhibition of breast cancer resistance protein ABCG2
Boumendjel, A., Macalou, S., Ahmed‐Belkacem, A., Blanc, M., & Pietro, A. D. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.02.017 · Cited by 92
Sauna, Z. E., Peng, X.-H., Nandigama, K., Tekle, S., & Ambudkar, S. V. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.675 · Cited by 91
Self-citationGandhi, L., Harding, M. W., Neubauer, M., Langer, C. J., Moore, M., Ross, H. J., Johnson, B. E., & Lynch, T. J. (2007) · Cancer · doi:10.1002/cncr.22492 · Cited by 90
The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.
Johnson, D. R., Finch, R. A., Lin, Z., Zeiss, C. J., & Sartorelli, A. C. (2001) · PubMed · Cited by 88
Saeki, T., Nomizu, T., Toi, M., Ito, Y., Noguchi, S., Kobayashi, T., Asaga, T., Minami, H., Yamamoto, N., Aogi, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1646 · Cited by 84
Pearson, J., Fogler, W. E., Völker, K., Usui, N., Goldenberg, S. K., Gruys, E., Riggs, C. W., Komschlies, K. L., Wiltrout, R. H., TSURUO, T., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.19.1386 · Cited by 82
Metabolites of ginsenosides as novel BCRP inhibitors
Jin, J., Shahi, S., Kang, H. K., van Veen, H. W., & Fan, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.152 · Cited by 81
Morschhauser, F., Zinzani, P. L., Burgess, M., Sloots, L., Bouafia, F., & Dumontet, C. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701190169 · Cited by 81
The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential
van Zanden, J. J., van der Woude, H., Vaessen, J., Usta, M., Wortelboer, H. M., Cnubben, N. H. P., & Rietjens, I. M. C. M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.04.002 · Cited by 81
Wang, S., Folkes, A. J., Chuckowree, I., Cockcroft, X. F., Sohal, S., Miller, W., Milton, J., Wren, S. P., Vicker, N., Depledge, P., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031011g · Cited by 80
Muñoz‐Martínez, F., Lu, P., Cortés-Selva, F., Pérez-Victoria, J. M., Jiménez, I. A., Ravelo, Á. G., Sharom, F. J., Gamarro, F., & Castanys, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1005 · Cited by 80
Jin, J., Wang, F., Wei, H., & Liu, G.-T. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0868-0 · Cited by 80
Krishna, R., & Mayer, L. D. (1997) · PubMed · Cited by 79
Pawarode, A., Shukla, S., Minderman, H., Fricke, S. M., Pinder, E., O’Loughlin, K. L., Ambudkar, S. V., & Baer, M. R. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0357-8 · Cited by 76
Self-citationReversal of cancer multidrug resistance by green tea polyphenols
Mei, Y., Qian, F., Wei, D., & Liu, J. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357044364 · Cited by 74
Effects of Kaempferia Parviflora Extracts and Their Flavone Constituents on P-glycoprotein Function
Patanasethanont, D., Nagai, J., Yumoto, R., Murakami, T., Sutthanut, K., Sripanidkulchai, B., Yenjai, C., & Takano, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20769 · Cited by 71
Jekerle, V., Klinkhammer, W., Scollard, D. A., Breitbach, K., Reilly, R. M., Piquette‐Miller, M., & Wiese, M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21827 · Cited by 70
Morita, H., Koyama, K., Sugimoto, Y., & Kobayashi, J. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.026 · Cited by 70
van Zuylen, L., Sparreboom, A., van der Gaast, A., Nooter, K., Eskens, F. A. L. M., Brouwer, E., Bol, C. J., de Vries, R., Palmer, P. A., & Verweij, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00035-7 · Cited by 69
Kanzaki, A., Takebayashi, Y., Ren, X. Q., Miyashita, H., Mori, S., Akiyama, S. I., & Pommier, Y. G. (2002) · PubMed · Cited by 69
Naito, M., Tsuge, H., Kuroko, C., Koyama, T., Tomida, A., Tatsuta, T., Heike, Y., & TSURUO, T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.311 · Cited by 67
Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1)
Norman, B. H., Gruber, J. M., Hollinshead, S. P., Wilson, J. W., Starling, J. J., Law, K. L., Self, T. D., Tabas, L. B., Williams, D. C., Paul, D. C., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00051-3 · Cited by 67
Limtrakul, P., Khantamat, O., & Pintha, K. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0848-4 · Cited by 63
O'Connor, R. A., O’Leary, M., Ballot, J., Collins, C. D., Kinsella, P., Mager, D. E., Arnold, R. D., O’Driscoll, L., Larkin, A., Kennedy, S., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0240-7 · Cited by 62
Reyno, L. M., Seymour, L., Tu, D., Dent, S. F., Gelmon, K. A., Walley, B. A., Pluzanska, A., Gorbunova, V. A., Garin, A., Jassem, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.075 · Cited by 62
Robey, R. W., Shukla, S., Steadman, K., Obrzut, T., Finley, E. M., Ambudkar, S. V., & Bates, S. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0811 · Cited by 61
Self-citationFong, W.-F., Wan, C.-K., Zhu, G.-Y., Chattopadhyay, A., Dey, S., Zhao, Z., & Shen, X.-L. (2007) · Planta Medica · doi:10.1055/s-2007-967120 · Cited by 57
Aoki, S., Cao, L.-W., Matsui, K., Rachmat, R., Akiyama, S., & Kobayashi, M. (2004) · Tetrahedron · doi:10.1016/j.tet.2003.07.020 · Cited by 56
Walter, R. B., Pirga, J., Cronk, M. R., Mayer, S. J., Appelbaum, F. R., & Banker, D. E. (2005) · Blood · doi:10.1182/blood-2005-02-0711 · Cited by 55
GANESHAGURU, K., Wickremasinghe, R. G., Jones, D. T., Gordon, M., Hart, S., Virchis, A. E., Prentice, H. G., Hoffbrand, A. V., Man, A., Champain, K., et al. (2002) · PubMed · Cited by 52
van Zanden, J. J., de Mul, A., Wortelboer, H. M., Usta, M., van BLADEREN, P. J., Rietjens, I. M. C. M., & Cnubben, N. H. P. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.001 · Cited by 52
Boumendjel, A., Nicolle, E., Moraux, T., Gerby, B., Blanc, M., Ronot, X., & Boutonnât, J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050705h · Cited by 51
Yoo, H., Lee, M., Lee, M., Lim, S., Shin, J., & Kim, D.-H. (2007) · Planta Medica · doi:10.1055/s-2007-967178 · Cited by 49
Li, L., Pan, Q., Sun, M., Lu, Q., & Hu, X. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.11.002 · Cited by 48
EXTRACTS AND KAVALACTONES OF PIPER METHYSTICUM G. FORST (KAVA-KAVA) INHIBIT P-GLYCOPROTEIN IN VITRO
Weiß, J., Sauer, A., Frank, A., & Unger, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005892 · Cited by 48
Effect of a Novel Vacuolar-H+-ATPase Inhibitor on Cell and Tumor Response to Camptothecins
Petrangolini, G., Supino, R., Pratesi, G., Bo, L. D., Tortoreto, M., Croce, A. C., Misiano, P., Belfiore, P., Farina, C., & Zunino, F. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103481 · Cited by 41
Nagata, J., Kijima, H., Hatanaka, H., et al. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.5.1021 · Cited by 38
Burg, D., Wielinga, P. R., Zelcer, N., SAEKI, T., Mulder, G. J., & Borst, P. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.5.1160 · Cited by 36
Hu, X. F., Li, J., Yang, E., Vandervalk, S., & Xing, P. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603641 · Cited by 30
Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein
Iwaki, K., Sakaeda, T., Kakumoto, M., et al. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.12.0008 · Cited by 25
Reversal of multidrug resistance by a liposome- MDR 1 ribozyme complex
Masuda, Y., Kobayashi, H., Holland, J. F., & Ohnuma, T. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050778 · Cited by 22
Mansilla, S., Rojas, M., Bataller, M., Priebe, W., & Portugal, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.12.005 · Cited by 21
Ferreira, M. U., Gyémánt, N., Madureira, A., et al. (2005) · PubMed · Cited by 18
Vincent, M. D. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.11.005 · Cited by 14
Binding Site(s) on P-Glycoprotein for a Newly Synthesized Photoaffinity Analog of Agosterol A
満尾, 雅., Noguchi, T., Nakajima, Y., Aoki, S., Ren, X., Sumizawa, T., Haraguchi, M., Kobayashi, M., Baba, M., Nagata, Y., et al. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/000000003108748595 · Cited by 11
Cited by
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
Xiong, X.-B., & Lavasanifar, A. (2011) · ACS Nano · doi:10.1021/nn2013707 · Cited by 411
Binkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Metadata
- Authors
- Shukla, S., Wu, C.-P., & Ambudkar, S. V.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2008-02
- Volume
- 4
- Issue
- 2
- Pages
- 205-223
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2069382823
- Cited by
- 253
- References
- 170
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.